Stockscreener 앱 받기
9.90
0.90%
-0.09
시간 외 거래:
9.90
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast By Investing.com - Investing.com India
Theravance Biopharma (TBPH) Reports Q1 Revenue and Strategic Progress | TBPH Stock News - GuruFocus
Theravance Biopharma Inc Surpasses Revenue Estimates with $58.3 Million in Q1 2025, Highlighting Strong Market Performance - GuruFocus
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by Barclays PLC - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Theravance Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
(TBPH) Investment Report - news.stocktradersdaily.com
Invesco Ltd. Has $433,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Legal & General Group Plc Reduces Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
BTIG lifts Theravance Biopharma stock target to $24 on TRELEGY sales - Investing.com
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress - PR Newswire
New Phase 3 Analysis Reveals Ampreloxetine Impact on MSA Patients with Orthostatic Hypotension - Stock Titan
Zacks Research Issues Positive Outlook for TBPH Earnings - Defense World
Rep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock - Defense World
Geode Capital Management LLC Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
JPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Russell Investments Group Ltd. Lowers Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Report First Quarter 2025 Financial Resu - GuruFocus
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 | TBPH Stock News - GuruFocus
Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World
(TBPH) Trading Signals - news.stocktradersdaily.com
Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks
Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World
5.73%
1.07%
자본화:
|
볼륨(24시간):